HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims on Behalf of Investors of Hims & Hers Health, Inc.

Kahn Swick & Foti, LLC (KSF) is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential fraud, negligence, or unlawful business practices on behalf of investors. This probe follows Novo Nordisk's June 23, 2025, termination of its partnership with Hims, citing Hims' alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the guise of 'personalization,' deceptive marketing practices, and patient safety risks, specifically concerning potentially illicit 'semaglutide' ingredients. The investigation aims to recover investment losses stemming from these alleged corporate malfeasance issues.

Analysis

Hims & Hers Health, Inc. (NYSE: HIMS) faces a significant legal and reputational crisis following the termination of its partnership with Novo Nordisk on June 23, 2025. The core of the issue stems from serious allegations made by Novo Nordisk, which claims Hims engaged in unlawful business practices, including the mass sale of compounded drugs under the 'false guise of personalization' and deceptive marketing that jeopardizes patient safety. The most damaging accusation involves the potential use of 'unsafe and illicit foreign ingredients' in its compounded semaglutide products. This has prompted an immediate investigation by the securities litigation firm Kahn Swick & Foti, LLC (KSF) for potential fraud and negligence on behalf of investors. These developments strike directly at the company's business model, credibility, and governance, creating substantial risk of regulatory action, legal liabilities from class-action lawsuits, and a severe erosion of consumer and investor confidence.

Key Decisions for Investors

• Given the severity of the allegations from a major partner and the initiation of a securities fraud investigation, investors should immediately re-evaluate any long positions in HIMS due to the elevated risk of significant stock price declines and protracted legal battles.
• Potential investors should view HIMS as a high-risk asset and avoid initiating new positions until the company provides a comprehensive and verifiable response to Novo Nordisk's claims and the legal situation gains more clarity.
• Monitor for key near-term catalysts, including any official response or guidance revision from Hims' management, filings from regulatory bodies like the FDA, and the formal filing of a class-action lawsuit, as these events will be critical determinants of the stock's trajectory.